Investigating how short inhibitory RNAs affect blood cell function
Short inhibitory RNAs in platelet and megakaryocyte function
['FUNDING_R01'] · THOMAS JEFFERSON UNIVERSITY · NIH-11048309
This study is looking at a new way to use tiny molecules to help control certain genes in blood cells, which could lead to better treatments for people dealing with blood clotting and bleeding issues, making it safer and more effective than current medications.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | THOMAS JEFFERSON UNIVERSITY (nih funded) |
| Locations | 1 site (PHILADELPHIA, UNITED STATES) |
| Trial ID | NIH-11048309 on ClinicalTrials.gov |
What this research studies
This research explores the use of short inhibitory RNAs (siRNAs) to selectively reduce the activity of specific genes in blood cells called megakaryocytes and platelets. By administering these siRNAs directly into the bloodstream, the study aims to improve antithrombotic treatments while maintaining better hemostatic protection compared to traditional drug therapies. The researchers will examine how these siRNAs can alter gene expression and function in these blood cells, potentially leading to more effective treatments for conditions related to blood clotting and bleeding. This innovative approach could provide insights into gene manipulation in blood cells without the need for complex delivery systems.
Who could benefit from this research
Good fit: Ideal candidates for this research would include individuals with conditions that require antithrombotic therapy or those at high risk for thrombotic events.
Not a fit: Patients who do not have issues related to blood clotting or bleeding may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective and safer treatments for patients at risk of blood clots or bleeding disorders.
How similar studies have performed: This approach is novel and has not been extensively tested in similar research, making it a potentially groundbreaking investigation.
Where this research is happening
PHILADELPHIA, UNITED STATES
- THOMAS JEFFERSON UNIVERSITY — PHILADELPHIA, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: GOLDFINGER, LAWRENCE E — THOMAS JEFFERSON UNIVERSITY
- Study coordinator: GOLDFINGER, LAWRENCE E
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.